- Home
- CMCL vs CHRS Comparison
CMCL vs CHRS Comparison
Compare CMCL & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMCL
- CHRS
- Stock Information
- Founded
- CMCL 1992
- CHRS 2010
- Country
- CMCL Jersey
- CHRS United States
- Employees
- CMCL N/A
- CHRS N/A
- Industry
- CMCL Precious Metals
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CMCL Basic Materials
- CHRS Health Care
- Exchange
- CMCL Nasdaq
- CHRS Nasdaq
- Market Cap
- CMCL 181.6M
- CHRS 191.3M
- IPO Year
- CMCL N/A
- CHRS 2014
- Fundamental
- Price
- CMCL $9.46
- CHRS $1.39
- Analyst Decision
- CMCL Buy
- CHRS Strong Buy
- Analyst Count
- CMCL 1
- CHRS 4
- Target Price
- CMCL $13.50
- CHRS $5.38
- AVG Volume (30 Days)
- CMCL 58.6K
- CHRS 2.0M
- Earning Date
- CMCL 11-11-2024
- CHRS 03-12-2025
- Dividend Yield
- CMCL 3.01%
- CHRS N/A
- EPS Growth
- CMCL N/A
- CHRS N/A
- EPS
- CMCL 0.48
- CHRS N/A
- Revenue
- CMCL $165,346,000.00
- CHRS $304,340,000.00
- Revenue This Year
- CMCL $29.34
- CHRS $2.47
- Revenue Next Year
- CMCL $7.57
- CHRS N/A
- P/E Ratio
- CMCL $19.16
- CHRS N/A
- Revenue Growth
- CMCL 22.97
- CHRS 44.19
- 52 Week Low
- CMCL $8.81
- CHRS $0.66
- 52 Week High
- CMCL $16.95
- CHRS $2.97
- Technical
- Relative Strength Index (RSI)
- CMCL 43.23
- CHRS 45.86
- Support Level
- CMCL $8.81
- CHRS $1.38
- Resistance Level
- CMCL $9.54
- CHRS $1.60
- Average True Range (ATR)
- CMCL 0.35
- CHRS 0.13
- MACD
- CMCL 0.12
- CHRS -0.03
- Stochastic Oscillator
- CMCL 52.61
- CHRS 9.52
About CMCL Caledonia Mining Corporation Plc
Caledonia Mining Corp PLC is a gold exploration, development, and mining company. The company's segment includes Blanket, South Africa, Bilboes Oxide mine, and E&E projects. The company generates the majority of its revenue from the blanket project. The Blanket Mine is located in the south-west of Zimbabwe and operates at a depth of approximately 750 meters below the surface. The company's project includes Maligreen and Motapa.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.